tirzepatide loss of exclusivity Drug Patents containing tirzepatide loss of exclusivity Compounded

today, some are approved to help treat obesity as well

Housebound: ICBs and Local Authorities should ensure appropriate delivery and support of equitable access for people who are housebound due to illness, frailty, surgery, and/or mental health

The Phase 3 program is comprised of three trials evaluating KAI-9531: one in adults with a BMI greater than 30 kg/m 2 or greater than 27 kg/m 2 with at least one comorbidity and without type 2 diabetes, another in adults with BMI of greater than 27 kg/m 2 and type 2 diabetes, and a third in adults with a BMI of greater than 35 kg/m 2 and without type 2 diabetes

(Please see below for additional information about compounded medications.) Approved for: Saxenda (liraglutide) is FDA-approved for chronic weight management in adults with obesity or overweight who also have weight-related health conditions

2025 Aug 25;22(Suppl 2):2550139

Muscle Loss Concern Both peptides cause significant weight loss, and a portion of that weight is lean mass